Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer

A predictive marker for efficacy of eribulin administered as different lines of treatment in metastatic breast cancer (MBC) has not been identified. We aimed to determine the predictive factors for efficacy of eribulin administered as different lines of treatment in MBC patients. This restrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Pei-Hsin, Yeh, Dah-Cherng, Tung, Heng-Hsin, Lin, Chin-Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615315/
https://www.ncbi.nlm.nih.gov/pubmed/34964753
http://dx.doi.org/10.1097/MD.0000000000027859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615315/
https://www.ncbi.nlm.nih.gov/pubmed/34964753
http://dx.doi.org/10.1097/MD.0000000000027859

Ejemplares similares